Brucine Entrapped Titanium Oxide Nanoparticle for Anticancer Treatment: An In Vitro Study

Figure 3

Representation of ROS staining by DCFHDA method. (a–d) represents Control, 15 µg/ml, 30 µg/ml and 60 µg/ml respectively. ROS release was high in treated groups as dose dependent manner, whereas control showed negligible amount of ROS released.

(a)

(b)

(c)

(d)